Rheumatology
Rheumatology Clinical Trials require specialised expertise due to the complexity of rheumatic diseases.
Accurate trial design, comprehensive safety monitoring, and effective patient engagement are critical to the successful evaluation of treatments for these chronic and debilitating conditions. At iNGENū CRO, we provide tailored, high-quality, and cost-effective solutions that accelerate the development of novel rheumatology therapies.
Our clinical team has comprehensive experience in a range of rheumatological conditions, including:
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Osteoarthritis (OA)
- Ankylosing Spondylitis (AS)
- Systemic Lupus Erythematosus (SLE)
- Juvenile Idiopathic Arthritis (JIA)
- Gout and Crystal Arthropathies
- Fibromyalgia
Disciplined,
Cost-Efficient Execution
while maintaining the Highest Quality
Local Trials,
Global Approvals
Access FDA Regulatory Expertise
Our Clinical Team has over
120
years
of Combined Clinical Trial Experience
Rheumatology Clinical Trial Resources
Cutaneous Lupus Erythematosus
Gain key insights into overcoming challenges in CLE Clinical Trials.
Osteoarthritis
Systemic lupus erythematosus trial strategies with multi-organ system endpoints.
Rheumatoid Arthritis
Navigating diagnosis, endpoints, and protocol enhancements in Rheumatoid Arthritis Clinical Trials.
Addressing Common Pain Points Associated with Rheumatology Clinical Trials
Subjectivity in Disease Assessments
Problem:
Rheumatology trials often rely on subjective assessments of disease activity and pain, leading to potential variability between evaluators and across sites.
iNGENū CRO addresses this pain point with Standardised and Objective Assessments:
iNGENū implements validated disease activity scores and patient-reported outcome measures (PROMs) such as DAS28, CDAI, or RAPID3. Comprehensive training and centralised review processes ensure consistency and accuracy in assessments across all trial sites.
Complexity of Biomarker and Imaging Techniques
Problem:
Rheumatology studies frequently involve sophisticated biomarkers and imaging techniques such as ultrasound, MRI, or X-rays to assess joint damage and inflammation.
iNGENū CRO addresses this pain point with Centralised Imaging and Biomarker Analysis:
Our centralised imaging platform ensures standardised protocols and expert analysis, minimising variability. We also utilise advanced biomarker laboratories with rigorous quality control measures to ensure reliable data collection.
Patient Recruitment and Retention
Problem:
Finding and retaining patients in rheumatology trials can be challenging due to disease variability, strict eligibility criteria, and the chronic nature of these conditions.
iNGENū CRO addresses this pain point with Tailored Recruitment Strategies:
iNGENū leverages robust patient databases, partnerships with rheumatology clinics, and collaborations with patient advocacy groups to efficiently identify and engage suitable candidates. Our patient-centric approach includes flexible scheduling, telehealth options, and continuous patient support to reduce dropout rates.
Placebo Effects and Treatment Bias
Problem:
The subjective nature of symptoms in rheumatic diseases can result in significant placebo responses, complicating trial result interpretation.
iNGENū CRO addresses this pain point with Rigorous Blinding and Statistical Techniques:
We employ robust blinding methods and innovative trial designs, such as crossover or withdrawal studies, to mitigate placebo effects. Our biostatisticians use advanced statistical analyses to accurately differentiate true treatment effects from placebo responses.
Safety Monitoring for Long-term Treatments
Problem:
Many rheumatology trials involve long-term treatments, such as biologics or immunosuppressants, which require vigilant safety monitoring due to potential adverse effects.
iNGENū CRO addresses this pain point with Comprehensive Safety Monitoring:
Our dedicated safety boards continuously monitor patient data, ensuring rapid identification and management of any adverse events. Our real-time safety reporting and proactive risk management protocols prioritise patient safety throughout the trial duration.
The iNGENū CRO Difference
Local Trials, Global Approvals
We uniquely combine Australian expertise with direct FDA submission capabilities.
Disciplined, Cost-Efficient Execution
iNGENū CRO takes a highly strategic approach to clinical research.
Australian-Headquartered, Asia-Pacific Reach
We provide sponsors with comprehensive trial capabilities.
We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug. We have been very happy with all aspects of the management of the clinical trial.
Ready to discuss your Rheumatology Clinical Trial?